Adlai Nortye Enrolls First Patient in Global Phase 1 AN9025 RAS‑Inhibitor Trial
Adlai Nortye launches first patient enrollment in global Phase‑1 trial of AN9025, a first‑in‑class oral pan‑RAS inhibitor targeting RAS‑mutant cancers, promising a new therapeutic option and potential market expansion.
3 minutes to read